Compare organizations

Forum, as a Slovenian R&D pharmaceutical industry association, hereby expresses its support of the European Commission's effort to build a regulatory framework which will ensure availability of innovative, effective and safe medicines throughout the whole European union and that all needs of European patients will be adequately addressed.

The evaluation and revision of the general pharmaceutical legislation is the opportunity to create a future-proof, patient-oriented and leading life sciences and biotechnology sector in the EU. New biotechnology-derived vaccines and treatments have helped to tackle numerous life-threatening illnesses. Targeted cell and gene therapies and new mRNA platforms are paving the way for future treatments.

In the last 20 years, biotech transformed the pharmaceutical industry and enabled the development of breakthrough therapies that are live-saving or significantly improving quality of life of patients and their families. The development of biotech in Europe also continues to positively contribute to the regions economic well-being.

FarmaForum, the Slovenian innovative pharmaceutical industry association recognizes the need for comprehensive regulations and standards and welcomes the European Commission legislative initiative aimed at modernising the pharmaceutical legislation.

FarmaForum, the Slovenian innovative pharmaceutical industry association recognizes the need for comprehensive regulations and standards and welcomes the European Commission legislative initiative aimed at modernising the pharmaceutical legislation.

Forum’s views on the proposed European Health Data Space (EHDS) Forum, the Slovenian innovative pharmaceutical association, which represents 21 global research companies, supports the Commission's efforts to generate a legal environment providing for a wide-ranging use, re-use and exchange of health data, acknowledging the value of such data and promoting the harmonization of digital standards, both at the EU and at…

EuropaBio welcomes the EC's plan to begin a discussion with stakeholders to develop the EHDS. Science is evolving fast and digital tools are accelerating our ability to conduct research. For the biotechnology industry, it is imperative quality data sets are collected and analysed, while protecting privacy and maintaining trust in how the data are used.

In Forum, the Slovenian innovative pharmaceutical association, which represents 22 global research companies, we are aware, that to date, the Paediatric and Orphan Regulations have provided immense benefits for children and patients with rare diseases (RD) in Slovenia. We would welcome Commission’s effort to maintain the legislative framework which would ensure possibilities to treat DS also in the future.

Developing medicines for children and rare diseases is a lengthy and complex undertaking. Much less is known about these illnesses when compared to more common conditions, meaning extensive research is required before scientists and researchers can seek to transform their ideas into potential treatments.

Forum of International Research and Development Pharmaceutical Companies, EIG (FarmaForum), as a Slovenian innovative pharma industry association, expresses its concern regarding the European Commission's (EC) proposal of the new compulsory licensing legislation. The EC's proposal introduces a new right to issue compulsory licenses throughout the EU, which the EC would activate in a "crisis" situation.

The COVID-19 pandemic has shown the importance for Europe to have the right tools to respond to major health crises. The EU has already adopted several laws to improve its ability to respond to health emergencies and the coordination between the Member States.